Biosig to host conference call to unblind clinical data collected with its signal processing technology for arrhythmia care

Westport, ct, july 12, 2021 (globe newswire) -- biosig technologies, inc. (nasdaq: bsgm) (“biosig” or the “company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ecg and intra-cardiac signals, today announced that it would host a call to discuss the recent conclusions of its pure ep(tm) 2.0 study, which enrolled 51 patients at texas cardiac arrhythmia institute at st. david's medical center in austin, tx, mayo clinic florida campus in jacksonville, fl and massachusetts general hospital in boston, ma.
BSGM Ratings Summary
BSGM Quant Ranking